A tumor’s ‘signature’ reveals the key to treatment in precision oncology
A potential response to cancer is written — on a microscopic level — in its very tumor cells. For decades, treatment and prognosis of the disease has been largely determined by the organ, the anatomical location in which the cancerous mass is located. But now, science has placed a spotlight on something more ambitious: learning the tumor’s signature, or rather, the molecular alterations that characterize its malignant cells. The latest meeting of the American Society of Clinical Oncology (ASCO), which took place last weekend in Chicago, has given further impetus to precision oncology and highlighted how cancer biology, those microscopic genetic characteristics that define it, are playing an increasingly important role in determining therapeutic approach, and even predicting prognosis.

© Lukas Kabon (Anadolu Agency / Getty)


